Head and Neck Protocols
As of July 8, 2013 - protocols do open and close daily.
Please check with your physician for additional protocols and/or information.
1. E1305: A Phase III Randomized Trial of Cisplatin & Docetaxel with or without Bevacizumab in Patients with Recurrent or Metastatic Head & Neck Cancer
The purpose of this study is to compare the effects (good and bad) of the addition of a drug called bevacizumab to the standard chemotherapy to see which works better.
2. RTOG 0920: A Phase III Study of Radiation Therapy (IMRT) +/- Cetuximab (C225) for Intermediate Risk Resected Head and Neck Cancer
The purpose of this study is to compare the effects, good and/or bad, of radiation therapy alone with radiation therapy and cetuximab on you and your cancer to find out which is better. In this study, you will get either radiation therapy alone OR radiation therapy and cetuximab.
3. RTOG 1016: Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer
The purpose of this study is to compare the effects, good and/or bad, of two standard treatments for head and neck cancer: radiation therapy and cisplatin or radiation therapy and cetuximab. The two treatments may be comparable in treating your cancer, but radiation and cetuximab may result in less severe side effects.
Cisplatin is a classic chemotherapy drug. Cetuximab is a drug that blocks the epidermal growth factor receptor, a protein that affects cancer growth and many other functions. Radiation and cetuximab may result in less severe side effects. However, it is unknown whether it is equally effective as radiation and cisplatin for your type of cancer.
This study is being done in patients whose head and neck cancer was caused by Human Papillomavirus Virus (HPV). Some studies have found that patients with HPV positive oropharynx cancer have a better response to treatment and live longer. Thus, this study aims to see if treatment with radiation plus cetuximab has less side effects and is as effective as radiation plus cisplatin.
For more information on these protocols or any other research, please contact your physician or our clinical research coordinator, Jessica Gerlach, CCRP at 845-333-1133
To read more about our Head and Neck Cancer Services and additional Oncology Services, please view our 2011 Oncology Annual Report.